JP2017501738A - Cpmvエンハンサーエレメント - Google Patents
Cpmvエンハンサーエレメント Download PDFInfo
- Publication number
- JP2017501738A JP2017501738A JP2016545837A JP2016545837A JP2017501738A JP 2017501738 A JP2017501738 A JP 2017501738A JP 2016545837 A JP2016545837 A JP 2016545837A JP 2016545837 A JP2016545837 A JP 2016545837A JP 2017501738 A JP2017501738 A JP 2017501738A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- plant
- seq
- construct
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000723655 Cowpea mosaic virus Species 0.000 title claims abstract description 158
- 108700028146 Genetic Enhancer Elements Proteins 0.000 title description 33
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 242
- 239000002773 nucleotide Substances 0.000 claims abstract description 241
- 230000014509 gene expression Effects 0.000 claims abstract description 222
- 108020003589 5' Untranslated Regions Proteins 0.000 claims abstract description 111
- 239000003623 enhancer Substances 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 123
- 102000004169 proteins and genes Human genes 0.000 claims description 94
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 72
- 238000010367 cloning Methods 0.000 claims description 72
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 51
- 150000007523 nucleic acids Chemical group 0.000 claims description 51
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 51
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 241000723607 Comovirus Species 0.000 claims description 18
- 108090000051 Plastocyanin Proteins 0.000 claims description 14
- 230000030279 gene silencing Effects 0.000 claims description 14
- 239000000185 hemagglutinin Substances 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 101710154606 Hemagglutinin Proteins 0.000 claims description 13
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 13
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 13
- 101710176177 Protein A56 Proteins 0.000 claims description 13
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 10
- 208000037798 influenza B Diseases 0.000 claims description 8
- 108010067390 Viral Proteins Proteins 0.000 claims description 7
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 54
- 241000196324 Embryophyta Species 0.000 description 313
- 229960004641 rituximab Drugs 0.000 description 59
- 101710085938 Matrix protein Proteins 0.000 description 50
- 101710127721 Membrane protein Proteins 0.000 description 50
- 239000012634 fragment Substances 0.000 description 47
- 125000003275 alpha amino acid group Chemical group 0.000 description 40
- 101150033195 Victoria gene Proteins 0.000 description 36
- 230000002797 proteolythic effect Effects 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 31
- 108091081024 Start codon Proteins 0.000 description 28
- 108091026890 Coding region Proteins 0.000 description 27
- 208000037797 influenza A Diseases 0.000 description 22
- 108091036066 Three prime untranslated region Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 230000037430 deletion Effects 0.000 description 19
- 238000012217 deletion Methods 0.000 description 19
- 241000219823 Medicago Species 0.000 description 18
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 18
- 108010058731 nopaline synthase Proteins 0.000 description 18
- 108091023045 Untranslated Region Proteins 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 241000589158 Agrobacterium Species 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 238000013519 translation Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 210000005220 cytoplasmic tail Anatomy 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 239000002028 Biomass Substances 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 6
- 101150084101 RNA2 gene Proteins 0.000 description 6
- 101100353432 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP2 gene Proteins 0.000 description 6
- 108700009124 Transcription Initiation Site Proteins 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 241000272525 Anas platyrhynchos Species 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- -1 antibody Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108700013796 Citrus tristeza virus p23 Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 101800000653 Helper component proteinase Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000710145 Tomato bushy stunt virus Species 0.000 description 3
- 101900024951 Tomato bushy stunt virus RNA silencing suppressor p19 Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000003630 growth substance Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000037039 plant physiology Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241001529459 Enterovirus A71 Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000905450 Grapevine leafroll-associated virus 2 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000207746 Nicotiana benthamiana Species 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 101710091688 Patatin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 108700001094 Plant Genes Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000009894 physiological stress Effects 0.000 description 2
- 230000008121 plant development Effects 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- 101150073246 AGL1 gene Proteins 0.000 description 1
- 101710197633 Actin-1 Proteins 0.000 description 1
- 108090000104 Actin-related protein 3 Proteins 0.000 description 1
- 101100125297 Agrobacterium vitis (strain S4 / ATCC BAA-846) iaaH gene Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241001136800 Anas acuta Species 0.000 description 1
- 241001293113 Anas clypeata Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 101710151325 B2 protein Proteins 0.000 description 1
- 241001429249 Blueberry scorch virus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150064755 CKI1 gene Proteins 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 241001515826 Cassava vein mosaic virus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 241001168968 Chroicocephalus ridibundus Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101900178036 Cucumber mosaic virus Suppressor of silencing 2b Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241001492240 Grapevine virus A Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 235000021506 Ipomoea Nutrition 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
- 102100032965 Myomesin-2 Human genes 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 101150005851 NOS gene Proteins 0.000 description 1
- 101710202365 Napin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 241000710181 Potato virus M Species 0.000 description 1
- 241000710179 Potato virus S Species 0.000 description 1
- 241000709992 Potato virus X Species 0.000 description 1
- 241000723762 Potato virus Y Species 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 241000708500 Tomato crinkle virus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 101150046289 tms2 gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明は、植物における目的のタンパク質の発現に関する。本発明はまた、植物における目的のタンパク質の生産のための方法および組成物を提供する。
1)目的のタンパク質をコードする目的のヌクレオチド配列は、5’UTR配列、例えばCPMVX(ここでX=配列番号:1のヌクレオチド160、155、150、114である)のすぐ後の発現エンハンサーの3’末端に融合されてもよい。この例では、目的のヌクレオチド配列は、マルチプルクローニングサイトを有しない5’UTRに融合され、かつ目的のヌクレオチド配列は、目的のヌクレオチド配列のATG開始部位のすぐ上流の5’末端で植物コザック配列を含んでもよい(図1Bを参照されたい)。配列番号:1のヌクレオチド150−160、または155−160はコザック様配列を含むので、もしX=160(すなわちCPMV160)ならば、CPMV160に作動可能に連結される目的のヌクレオチド配列は、その5’末端に融合される植物コザック配列を必要としなくてもよい。しかしながら、所望であればCPMV160を含む構築物において、植物コザック配列は含まれてもよい(図1Bを参照されたい:「+/−植物コザック」)。もしX−155、150、または114ならば、CPMV155、CPMV150、またはCPMV114を含む構築物において目的のヌクレオチド配列の5’末端に融合される植物コザック配列を含むことが、目的のヌクレオチド配列の最適な発現のために推奨される。
2)目的のヌクレオチド配列は、発現エンハンサーの3’末端で植物コザック配列を含むCMPVX+発現エンハンサー(ここでX=配列番号:1の160、155、150、114である)に融合されてもよく、結果、目的のヌクレオチド配列が植物コザック配列のすぐ後に位置する。この例では、CPMVX+に融合される目的のヌクレオチド配列は、マルチプルクローニングサイトまたは植物コザック配列を含まないだろう(得られる構築物は図1Bにおいて示されるものに類似するだろう)。
3)目的のヌクレオチド配列は、発現エンハンサーの3’末端でマルチプルクローニングサイト(MCS)を含むCPMVX+発現エンハンサー(ここでX=配列番号:1の160、155、150、114である)に、マルチプルクローニングサイトを用いて、融合されてもよい。この例では、発現エンハンサーのマルチプルクローニングサイトおよび目的のヌクレオチド配列のATG開始部位からすぐ上流の植物コザック配列との融合を可能にするために、目的のヌクレオチド配列はその5’末端に対応する配列を含んでもよい(図1Cを参照されたい)。
を含むCPMV150+を含んでもよい。
caA(A/C)a (配列番号:5;植物界)
aaA(A/C)a (配列番号:6;双子葉植物)
aa(A/G)(A/C)a (配列番号:7;シロイヌナズナ)
植物コザック配列はまた:
AGAAA (配列番号:8)
AGACA (配列番号:9)
AGGAA (配列番号:10)
AAAAA (配列番号:11)
AAACA (配列番号:12)
AAGCA (配列番号:13)
AAGAA (配列番号:14)
AAAGAA (配列番号:15)
AAAGAA (配列番号:16)
(A/−)A(A/G)(A/G)(A/C)A.(配列番号:3;コンセンサス配列)
の群から選択されてもよい(図4を参照されたい)。
H1 A/California/07/2009(「PDI−H1 Cal」、または「H1 A/California/07/2009」):CPMV160+ベースの構築物番号1897、CPMV HTベースの構築物番号484(実施例5を参照されたい);
H3 A/Victoria/361/2011(「PDI−H3 Vic」、または「H3 A/Victoria/361/2011」):CPMV160+ベースの構築物番号1800;CPMV HTベースの構築物番号1391(それぞれ実施例1および2を参照されたい);
天然シグナルペプチドを有するインフルエンザA/Indonesia/5/2005由来のH5(WtSp−H5 Indo):CPMV160+ベースの構築物番号1880;CPMV HTベースの構築物番号489(実施例6を参照されたい);
欠失タンパク質分解ループを有し、かつ天然シグナルペプチドを有するB/Wisconsin/1/2010(「WtSp−B Wis−PrL」、または「B/Wisconsin/1/2010」):CPMV160+ベースの構築物番号1975;CPMV HTベースの構築物番号1445(実施例13を参照されたい);
欠失タンパク質分解ループを有し、かつPDIシグナルペプチドを有するB Brisbane/60/08(「B Brisbane/60/08」):CPMV160+ベースの構築物番号1937;CMPV HTベースの構築物番号1039(実施例9を参照されたい);
膜貫通ドメインおよび細胞質側末端に融合される欠失タンパク質分解ループを有し、かつPDIシグナルペプチドを有するB Brisbane/60/08+H1Tm(「B Brisbane/60/08+H1Tm」):CPMV160+ベースの構築物番号1977;CMPV HTベースの構築物1067(実施例10を参照されたい)、
欠失タンパク質分解ループを有し、かつPDIシグナルペプチドを有するB Massachusetts/2/2012 2012(「B Massachusetts/2/2012 2012」):CPMV160+ベースの構築物番号2050;CPMV HTベースの構築物番号2072(実施例11を参照されたい)、
膜貫通ドメインおよび細胞質側末端に融合される欠失タンパク質分解ループを有し、かつPDIシグナルペプチドを有するB Massachusetts/2/2012+H1Tm(「B Massachusetts/2/2012+H1Tm」):CPMV160+ベースの構築物番号2060;CPMV HTベースの構築物2074(実施例12を参照されたい)、
膜貫通ドメインおよび細胞質側末端に融合される欠失タンパク質分解ループを有し、かつ天然シグナルペプチドを有するB Wisconsin/1/2010+H1Tm(「B Wisconsin/1/2010+H1Tm」):CPMV160+ベースの構築物番号1893;CPMV HTベースの構築物1454(実施例14を参照されたい);
天然またはPDIシグナルペプチドを有するCPMV−HT(「CPMV−HT/野生型SP」および「CPMV−HT/PDISP」;構築物番号5001および5002、それぞれ、実施例15および16を参照されたい)、またはCPMV160+(「CPMV160+/野生型SP」および 「CPMV160+/PDISP」;構築物番号2100および2109、それぞれ実施例15および16を参照されたい)の制御下の、リツキシマブ(Rituxan)
と作動可能に連結されるCPMV−HT(従来技術)発現構築物およびCPMV160+ベースの発現構築物を含む植物において生産されるタンパク質の発現の比較が示されている。
iLXiYystvAiSslXlXXmlagXsXwmcs(配列番号:78)
ATGGCAACTACTAAAACTTTTTTAATTTTATTTTTTATGATATTAGCAACTACTAGTTCAACATGTGCT(配列番号:79)である。
パタチンシグナルペプチドのアミノ酸配列は:
MATTKTFLILFFMILATTSSTCA(配列番号:80)である。
2:PDI−アルファルファタンパク質ジスルフィドイソメラーゼ
3:WT−野生型または天然
4:TMCT−膜貫通ドメインおよび細胞質側末端
−配列番号:1、2、24、27、68、69および70−77のいずれか1つ、または配列番号:1、2、24、27、68、69および70−77のいずれか1つに記載の配列に100%、99%、98%、97%、96%、95%、90%、85%もしくは80%の同一性を示すヌクレオチド配列から選択されるコモウイルス 5’UTRを含む発現エンハンサーであって、ここで、当該発現エンハンサーは、本明細書に記載される植物制御領域および植物コザック配列に作動可能に連結される場合に、同一の植物制御領域を用いてCMPV HT(配列番号:4;不完全なMタンパク質を含む従来技術のエンハンサー配列、Sainsbury F.,and Lomonossoff G.P.,2008,Plant Physiol. 148:pp.1212−1218に記載される;出典明示により本明細書に組み込まれる)に融合される目的のヌクレオチド配列の発現レベルと比較される場合、発現エンハンサーに作動可能に連結される目的のヌクレオチド配列の発現レベルを増加させるものである、発現エンハンサーを提供する。
−上記で定義されるようなコモウイルス−ベースの発現エンハンサーもしくは発現カセット、プロモーター(制御領域)、任意にポリリンカー、コザック配列、目的のタンパク質をコードする核酸、ならびにターミネーターを含む1つ以上の発現系を提供する。
−本明細書に記載される1つ以上の発現系またはベクターを用いて、植物などの宿主生物において目的のタンパク質を発現する方法を提供する。
−本発明の1つ以上の発現系またはベクターから目的のタンパク質を発現する宿主細胞および生物、ならびに当該宿主および生物を生産する方法を提供する。
IF−HT1*(−Mprot)−PDI.c(図9A、配列番号:31)、
IF−HT2*(−Mprot)−PDI.c(図9B、配列番号:32)、
IF−HT3*(−Mprot)−PDI.c(図9C、配列番号:33)
IF−HT4*(−Mprot)−PDI.c(図9D、配列番号:34)
IF−HT5*(−Mprot)−PDI.c(図9E、配列番号:35)
IF−HT6*(−Mprot)−PDI.c(図9F、配列番号:36)
IF−HT7*(−Mprot)−PDI.c(図9G、配列番号:37)および
IF−HT8*(−Mprot)−PDI.c(図9H、配列番号:38)、
構築物番号1992から1999をそれぞれ作製するためのプライマー。プラスミド1992の表示は図9Iに示されている。類似する特徴を用いて構築物1993−1999を調製した。
市販の基材ピートモスで満たされる平地で、種子からニコチアナ・ベンサミアナ(Nicotiana benthamiana)植物を生長させた。当該植物を16/8光周期および、日中25℃/夜20℃の温度管理体制下で温室において生長するようにした。播種から3週間後、個々の苗木を取り出し、鉢に移植し、かつ同じ環境条件下でさらに3週間温室で生長させた。
インキュベーション後、植物の地上の一部を採取し、−80℃で凍結し、かつ破砕した。3倍容積の、冷50mM Tris pH8.0、0.15M NaCl、0.1% Triton X−100および1mM フッ化フェニルメチルスルホニル(phenylmethanesulfonyl fluoride)において、凍結−破砕の植物物質のそれぞれのサンプルをホモジナイズ(Polytron)することで総可溶性タンパク質を抽出した。ホモジナイゼーション後、スラリーを4℃で10分間、10,000gで遠心分離し、かつこれらの清澄粗抽出物(上清)を解析のために保存した。
CBER: Center for Biologics Evaluation and Research, Rockville, MD, USA.
Sino: Sino Biological inc., Beijing, China.
TGA: Therapeutic Goods Administration, Australia.
NIBSC: National Institute for Biological Standards and Control, United Kingdom
ITC: Immune Technology Corp., New York, NY, USA
Claims (23)
- XヌクレオチドからなるCPMV 5’UTRヌクレオチド配列(CMPVX)であって、X=配列番号:1の160、155、150、もしくは114である配列を含む、またはCMPVXと約80%から100%の配列類似性を含むヌクレオチド配列であって、ヌクレオチドX=配列番号:1配列番号:1の160、155、150、もしくは114である配列からなる、発現エンハンサー。
- CMPV 5’UTRヌクレオチド配列の3’末端に融合される、約1から100ヌクレオチド長のスタッファー配列をさらに含む、請求項1に記載の発現エンハンサー(CMPVX+、ここでX=配列番号:1の160、155、150、もしくは114である)。
- スタッファー配列が植物コザック配列を含む、請求項2に記載の発現エンハンサー。
- スタッファー配列が、マルチプルクローニングサイトをさらに含む、請求項3に記載の発現エンハンサー。
- コザック配列が配列番号:5−17に示される配列の群から選択される、請求項3に記載の発現エンハンサー。
- 配列番号:2のヌクレオチド配列を含む、請求項2に記載の発現エンハンサー。
- 配列番号:24、27、68、69、70および71の群から選択されるヌクレオチド配列を含む、請求項1に記載の発現エンハンサー。
- 配列番号:72、73、74、75、76および77の群から選択されるヌクレオチド配列を含む、請求項2に記載の発現エンハンサー。
- 請求項1に記載の発現エンハンサーおよび目的のヌクレオチド配列と作動可能に連結される制御領域を含む核酸配列を含む、植物発現系。
- コモウイルス3’UTRをさらに含む、請求項9に記載の植物発現系。
- サイレンシングのサプレッサーをコードする第二の核酸配列をさらに含む、請求項9に記載の植物発現系。
- サイレンシングのサプレッサーが、HcProおよびp19の群から選択される、請求項11に記載の植物発現系。
- 制御領域がプラストシアニンプロモーター、CaMV 35Sプロモーター、2xCaMV35Sプロモーター、CASプロモーター、RbcSプロモーター、Ubiプロモーター、またはアクチンプロモーターから選択される、請求項9に記載の植物発現系。
- 目的のヌクレオチド配列がウイルスタンパク質または抗体をコードする、請求項9に記載の植物発現系。
- ウイルスタンパク質がH1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、H16、およびインフルエンザB型ヘマグルチニンからなる群から選択されるインフルエンザヘマグルチニンである、請求項14に記載の植物発現系。
- ウイルスタンパク質または抗体をコードするヌクレオチド配列が、天然シグナルペプチド配列または非天然シグナルペプチドを含む、請求項14に記載の植物発現系。
- 非天然シグナルペプチドがタンパク質ジスルフィドイソメラーゼ(PDI)由来である、請求項16に記載の植物発現系。
- 請求項9に記載の植物発現系を、植物または植物の部分に導入すること、および目的のタンパク質をコードするヌクレオチド配列の発現を可能にする条件下で、植物もしくは植物の部分をインキュベートすることを含む、植物または植物の部分において目的のタンパク質を生産する方法。
- 請求項9に記載の植物発現系を用いて一過性に遺伝子導入されている、または安定的に形質転換されている、植物または植物の部分。
- 目的のヌクレオチド配列に作動可能に連結される、請求項1に記載の発現エンハンサーを含む核酸。
- 目的のヌクレオチド配列が、B HA、C、H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、およびH16から選択されるインフルエンザヘマグルチニン(HA)である、請求項20に記載の核酸。
- HAが、HAの天然膜貫通ドメインが異種の膜貫通ドメインと置き換わっている、キメラHAである、請求項21に記載の核酸。
- 異種の膜貫通ドメインがH1 Californiaから得られる、請求項22に記載の核酸。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925852P | 2014-01-10 | 2014-01-10 | |
US61/925,852 | 2014-01-10 | ||
CAPCT/CA2014/050326 | 2014-03-28 | ||
PCT/CA2014/050326 WO2014153674A1 (en) | 2013-03-28 | 2014-03-28 | Influenza virus-like particle production in plants |
PCT/CA2015/050009 WO2015103704A1 (en) | 2014-01-10 | 2015-01-08 | Cpmv enhancer elements |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017501738A true JP2017501738A (ja) | 2017-01-19 |
JP2017501738A5 JP2017501738A5 (ja) | 2018-02-15 |
JP6518257B2 JP6518257B2 (ja) | 2019-05-22 |
Family
ID=53523412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016545837A Active JP6518257B2 (ja) | 2014-01-10 | 2015-01-08 | Cpmvエンハンサーエレメント |
Country Status (12)
Country | Link |
---|---|
US (2) | US11441150B2 (ja) |
EP (1) | EP3092309B1 (ja) |
JP (1) | JP6518257B2 (ja) |
CN (1) | CN105980561B (ja) |
AU (1) | AU2015205805B2 (ja) |
BR (1) | BR112016015875A2 (ja) |
CA (1) | CA2936350C (ja) |
DK (1) | DK3092309T3 (ja) |
ES (1) | ES2864081T3 (ja) |
RU (1) | RU2699982C2 (ja) |
TW (1) | TWI714522B (ja) |
WO (1) | WO2015103704A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516977A (ja) * | 2018-03-14 | 2021-07-15 | メディカゴ インコーポレイテッド | 植物発現エンハンサ |
JP2022534464A (ja) * | 2019-03-14 | 2022-08-01 | 田辺三菱製薬株式会社 | 内因性植物発現エンハンサー |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0800272D0 (en) | 2008-01-08 | 2008-02-13 | Plant Bioscience Ltd | Protein expression systems |
JP6518257B2 (ja) * | 2014-01-10 | 2019-05-22 | メディカゴ インコーポレイテッド | Cpmvエンハンサーエレメント |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011509081A (ja) * | 2008-01-08 | 2011-03-24 | プラント・バイオサイエンス・リミテッド | タンパク質発現系 |
JP2012530499A (ja) * | 2009-06-24 | 2012-12-06 | メディカゴ インコーポレイテッド | ヘマグルチニンを含むキメラインフルエンザウイルス様粒子 |
WO2013044390A1 (en) * | 2011-09-30 | 2013-04-04 | Medicago Inc. | Increasing virus-like particle yield in plants |
JP2013545454A (ja) * | 2010-11-04 | 2013-12-26 | メディカゴ インコーポレイテッド | 植物発現系 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9414118D0 (en) | 1994-07-13 | 1994-08-31 | Axis Genetics Ltd | Modified plant viruses as vectors of heterologous peptides |
US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
US20010006950A1 (en) | 1998-02-11 | 2001-07-05 | Juha Punnonen | Genetic vaccine vector engineering |
US6489537B1 (en) | 1998-08-07 | 2002-12-03 | The Trustees Of The University Of Pennsylvania | Phytochelatin synthases and uses therefor |
US6287570B1 (en) | 1998-11-23 | 2001-09-11 | Patricia L. Foley | Vaccine against swine influenza virus |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
CA2406668C (en) | 1999-12-06 | 2015-11-24 | Board Of Trustees Of The University Of Illinois | High affinity tcr proteins and methods |
DE10109354A1 (de) | 2001-02-27 | 2002-09-05 | Icon Genetics Ag | Rekombinante virale Schaltersysteme |
MXPA05006983A (es) * | 2002-12-27 | 2006-02-22 | Ct Ingenieria Genetica Biotech | Promotor artificial para la expresion de secuencias de acido desoxirribonucleico en celulas vegetales. |
EP1620550B1 (en) | 2003-05-05 | 2010-07-07 | Boyce Thompson Institute For Plant Research | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
WO2004098530A2 (en) | 2003-05-05 | 2004-11-18 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
EP2581093B1 (en) | 2003-06-16 | 2015-03-18 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
ES2662118T3 (es) | 2005-04-29 | 2018-04-05 | University Of Cape Town | Expresión de proteínas virales en las plantas |
MX2008000890A (es) | 2005-07-19 | 2008-03-18 | Dow Global Technologies Inc | Vacunas de influenza (flu) recombinantes. |
TWI488968B (zh) | 2005-10-18 | 2015-06-21 | Novavax Inc | 功能性流行性感冒類病毒顆粒(VLPs) |
CA2642054C (en) | 2006-02-13 | 2017-11-21 | Fraunhofer Usa, Inc. | Influenza antigens, vaccine compositions, and related methods |
ES2534332T3 (es) | 2006-03-07 | 2015-04-21 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
US7618815B2 (en) | 2006-03-08 | 2009-11-17 | University Of Kentucky Research Foundation | Viral vectors useful in soybean and methods of use |
EP2029755A1 (en) * | 2006-05-22 | 2009-03-04 | Plant Bioscience Limited | Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants |
US8697088B2 (en) | 2007-05-25 | 2014-04-15 | Novavax, Inc. | VLPs derived from cells that do not express a viral matrix or core protein |
PT2610345E (pt) | 2007-11-27 | 2016-01-11 | Medicago Inc | Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina |
GB0724752D0 (en) * | 2007-12-19 | 2008-01-30 | Bari Mazhar A | Method for producing a thermoelectric material |
KR101956910B1 (ko) * | 2008-01-21 | 2019-03-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs) |
AU2010234849B2 (en) | 2009-03-30 | 2017-06-22 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
EP2473616A4 (en) | 2009-09-04 | 2013-06-12 | Syngenta Participations Ag | STACKING OF TRANSLATION REINFORCING ELEMENTS FOR INCREASING POLYPEPTIDE EXPRESSION IN PLANTS |
PT2480560T (pt) | 2009-09-22 | 2018-04-03 | Medicago Inc | Método de preparação de proteínas derivadas de plantas |
AU2011312178B2 (en) | 2010-10-04 | 2016-05-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
TWI526539B (zh) | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
MX350421B (es) | 2011-06-13 | 2017-09-06 | Medicago Inc | Producción de partículas tipo virus de la rabia en plantas. |
PL220281B1 (pl) | 2011-09-23 | 2015-09-30 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA |
EP2776063B1 (en) * | 2011-11-11 | 2019-04-03 | Philip Morris Products S.a.s. | Influenza virus-like particles (vlps) comprising hemagglutinin produced in nicotiana tabacum |
JP6205359B2 (ja) | 2012-07-23 | 2017-09-27 | 有限会社生物資源研究所 | ワクチン |
EP3626827A1 (en) * | 2013-03-28 | 2020-03-25 | Medicago Inc. | Influenza virus-like particle production in plants |
JP6518257B2 (ja) * | 2014-01-10 | 2019-05-22 | メディカゴ インコーポレイテッド | Cpmvエンハンサーエレメント |
WO2015143567A1 (en) * | 2014-03-27 | 2015-10-01 | Medicago Inc. | Modified cpmv enhancer elements |
-
2015
- 2015-01-08 JP JP2016545837A patent/JP6518257B2/ja active Active
- 2015-01-08 CA CA2936350A patent/CA2936350C/en active Active
- 2015-01-08 DK DK15735364.0T patent/DK3092309T3/da active
- 2015-01-08 ES ES15735364T patent/ES2864081T3/es active Active
- 2015-01-08 WO PCT/CA2015/050009 patent/WO2015103704A1/en active Application Filing
- 2015-01-08 TW TW104100482A patent/TWI714522B/zh active
- 2015-01-08 BR BR112016015875A patent/BR112016015875A2/pt not_active Application Discontinuation
- 2015-01-08 EP EP15735364.0A patent/EP3092309B1/en active Active
- 2015-01-08 US US15/110,696 patent/US11441150B2/en active Active
- 2015-01-08 CN CN201580007060.9A patent/CN105980561B/zh active Active
- 2015-01-08 AU AU2015205805A patent/AU2015205805B2/en active Active
- 2015-01-08 RU RU2016132865A patent/RU2699982C2/ru active
-
2020
- 2020-05-21 US US16/880,583 patent/US11884929B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011509081A (ja) * | 2008-01-08 | 2011-03-24 | プラント・バイオサイエンス・リミテッド | タンパク質発現系 |
JP2012530499A (ja) * | 2009-06-24 | 2012-12-06 | メディカゴ インコーポレイテッド | ヘマグルチニンを含むキメラインフルエンザウイルス様粒子 |
JP2013545454A (ja) * | 2010-11-04 | 2013-12-26 | メディカゴ インコーポレイテッド | 植物発現系 |
WO2013044390A1 (en) * | 2011-09-30 | 2013-04-04 | Medicago Inc. | Increasing virus-like particle yield in plants |
Non-Patent Citations (3)
Title |
---|
PLANT BIOTECHNOLOGY JOURNAL, 2008, VOL.6, P.82-92, JPN6018046262, ISSN: 0004006289 * |
PLANT BIOTECHNOLOGY JOURNAL, 209, VOL.7, P.682-693, JPN6018046264, ISSN: 0004006290 * |
PLANT PHYSIOLOGY, 2008, VOL.148, P.1212-1218, JPN6018046266, ISSN: 0004006291 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516977A (ja) * | 2018-03-14 | 2021-07-15 | メディカゴ インコーポレイテッド | 植物発現エンハンサ |
JP7423875B2 (ja) | 2018-03-14 | 2024-01-30 | メディカゴ インコーポレイテッド | 植物発現エンハンサ |
JP7423875B6 (ja) | 2018-03-14 | 2024-03-15 | メディカゴ インコーポレイテッド | 植物発現エンハンサ |
JP2022534464A (ja) * | 2019-03-14 | 2022-08-01 | 田辺三菱製薬株式会社 | 内因性植物発現エンハンサー |
Also Published As
Publication number | Publication date |
---|---|
CA2936350C (en) | 2023-01-31 |
TWI714522B (zh) | 2021-01-01 |
RU2016132865A (ru) | 2018-02-14 |
US11884929B2 (en) | 2024-01-30 |
ES2864081T3 (es) | 2021-10-13 |
RU2016132865A3 (ja) | 2018-08-28 |
EP3092309A4 (en) | 2017-06-28 |
TW201610154A (zh) | 2016-03-16 |
EP3092309A1 (en) | 2016-11-16 |
WO2015103704A1 (en) | 2015-07-16 |
JP6518257B2 (ja) | 2019-05-22 |
CA2936350A1 (en) | 2015-07-16 |
AU2015205805B2 (en) | 2020-11-12 |
AU2015205805A1 (en) | 2016-08-04 |
BR112016015875A2 (pt) | 2017-09-19 |
CN105980561A (zh) | 2016-09-28 |
DK3092309T3 (da) | 2021-04-12 |
US11441150B2 (en) | 2022-09-13 |
US20170029832A1 (en) | 2017-02-02 |
CN105980561B (zh) | 2020-06-02 |
US20200283784A1 (en) | 2020-09-10 |
EP3092309B1 (en) | 2021-02-24 |
RU2699982C2 (ru) | 2019-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011325827B2 (en) | Plant expression system | |
US11884929B2 (en) | CPMV enhancer elements | |
JP6599354B2 (ja) | 改変されたcpmvエンハンサーエレメント | |
JP7423875B6 (ja) | 植物発現エンハンサ | |
US20220154195A1 (en) | Endogenous plant expression enhancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6518257 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |